Effects of serum from breast cancer surgery patients receiving perioperative dexmedetomidine on breast cancer cell malignancy: A prospective randomized controlled trial

Effects of serum from breast cancer surgery patients receiving perioperative dexmedetomidine on breast cancer cell malignancy: A prospective randomized controlled trial

Abstract Adrenergic receptors (ARs) have gained attention for their involvement in breast cancer (BC) progression. Dexmedetomidine, a selective α2‐AR agonist, has been reported to increase the malignancy of BC cells in vitro or stimulate tumor growth in mice. However, clinical evidence is lacking. C...

Full description

Bibliographic Details
Main Authors: Yan Liu, Jiaxin Sun, Tong Wu, Xiaoying Lu, Yueyao Du, Hongwei Duan, Weifeng Yu, Diansan Su, Jinsong Lu, Jie Tian
Format: Article
Language:English
Published: Wiley 2019-12-01
Series:Cancer Medicine
Subjects:
breast cancer
cell malignancy
dexmedetomidine
general anesthesia
Online Access:https://doi.org/10.1002/cam4.2654

Similar Items

Similar Items